Program
ensifentrine
Also written as “Ensifentrine”, “RPL554” and “Ensifentrine 3 mg”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis · Asthma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 152 open or running | phase 3since Aug 19, 2020 | Nov 30, 2014 | Mar 1, 2027phase 2 · NCT05270525 |
| Nuance Pharma (shanghai) | 20 open or running | phase 3since Feb 14, 2023 | Feb 14, 2023 | none ahead |
- Named in Merck’s own pipeline as
ensifentrine (+) glycopyrrolate (MK-5884A)
, phase 2, as of Nov 2, 2026 (source).
Also a collaborator on its studies: laboratory-corporation-of-america and iqvia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 30, 2014.
- Sep 21, 2016Phase 2 study in Cystic FibrosisMerck · NCT02919995 · 10 enrolled · United Kingdom
- Jan 3, 2017Phase 2 study in Chronic Obstructive Pulmonary Disease ModerateMerck · NCT03028142 · 30 enrolled
- Feb 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT03443414 · 405 enrolled · Bulgaria, Czechia, Germany and more
- Sep 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT03673670 · 79 enrolled · United States, United Kingdom
- Jun 20, 2019Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04091360 · 40 enrolled · United Kingdom
- Aug 19, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04535986 · 763 enrolled · United States, Bulgaria, Czechia and more
- Sep 1, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04542057 · 790 enrolled · United States, Belgium, Bulgaria and more
- Feb 8, 2022Phase 2 study in Lung DiseasesMerck · NCT05270525 · 70 enrolled · United States
- Feb 14, 2023Nuance Pharma (shanghai)'s first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Nuance Pharma (shanghai)Nuance Pharma (shanghai) · NCT05758428 · 28 enrolled · China
- Feb 14, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNuance Pharma (shanghai) · NCT05743075 · 526 enrolled · China
- Jun 10, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT06460493 · 20 enrolled · United States
- Jun 3, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07016412 · 497 enrolled · United States
- Aug 11, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07132983 · 33 enrolled · United States
- Sep 30, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07874815 · 2,136 planned · United States
Ahead
- Mar 1, 2027Primary completion: phase 2 study in Lung DiseasesMerck · NCT05270525
- Apr 29, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07874815
TargetBeta
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-…”NCIt, read by Claude
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), ”NCIt, by rule
“Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor”ChEMBL 37, by rule
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07874815Pulmonary Disease, Chronic Obstructive · United States | 3 | Recruiting | Merck | Apr 29, 2029 | 2,136 |
| NCT07132983Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Merck | Nov 28, 2025 | 33 |
| NCT07016412Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Merck | Aug 17, 2026 | 497 |
| NCT06460493Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | Merck | Nov 26, 2024 | 20 |
| NCT05758428Pulmonary Disease, Chronic Obstructive · China | 1 | Completed | Nuance Pharma (shanghai) | Apr 18, 2023 | 28 |
| NCT05743075Pulmonary Disease, Chronic Obstructive · China | 3 | Completed | Nuance Pharma (shanghai) | Dec 6, 2024 | 526 |
| NCT05270525Lung Diseases · United States | 2 | Active, not recruiting | Merck | Mar 1, 2027 | 70 |
| NCT04542057Pulmonary Disease, Chronic Obstructive · United States, Belgium, Bulgaria and more | 3 | Completed | Merck | May 3, 2022 | 790 |
| NCT04535986Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more | 3 | Completed | Merck | Sep 12, 2022 | 763 |
| NCT04091360Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | Merck | Dec 10, 2020 | 40 |
| NCT03673670Pulmonary Disease, Chronic Obstructive · United States, United Kingdom | 2 | Completed | Merck | Nov 13, 2018 | 79 |
| NCT03443414Pulmonary Disease, Chronic Obstructive · Bulgaria, Czechia, Germany and more | 2 | Completed | Merck | Jan 23, 2018 | 405 |
| NCT03028142Chronic Obstructive Pulmonary Disease Moderate | 2 | Completed | Merck | Aug 2017 | 30 |
| NCT02919995Cystic Fibrosis · United Kingdom | 2 | Completed | Merck | Nov 3, 2017 | 10 |
| NCT02542254Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | Merck | Dec 2015 | 36 |
| NCT02427165Asthma · Sweden, United Kingdom | 2 | Completed | Merck | Nov 2015 | 29 |
| NCT02307162Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Merck | Jul 2015 | 112 |
How it is read
Names in the registry
- “Ensifentrine”, 7 entries
- “RPL554”, 4 entries
- “Ensifentrine 3 mg”, 2 entries
- “Ensifentrine 1.5 mg”, 1 entry
- “Ensifentrine 3 mg (marketed formulation)”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 15 studies
- Cystic Fibrosis, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.